|Other Names||Chromosome transmission fidelity protein 8 homolog isoform 2, Decreased expression in renal and prostate cancer protein, CHTF8, DERPC|
|Target/Specificity||The synthetic peptide sequence is selected from aa 364-377 of HUMAN CHTF8|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Potential tumor suppressor. Inhibits prostate tumor cell growth, when overexpressed.|
|Tissue Location||Ubiquitously expressed, with abundant expression in kidney, skeletal muscle, testis, liver, ovary, and heart and moderate expression in prostate. Expression is significantly reduced in renal and prostate tumors. No differential expression in breast cancer cells, between lobular carcinoma and normal lobules.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Potential tumor suppressor. Inhibits prostate tumor cell growth, when overexpressed.
Bechtel S.,et al.BMC Genomics 8:399-399(2007).
Martin J.,et al.Nature 432:988-994(2004).
Mural R.J.,et al.Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
Sun M.,et al.Mol. Med. 8:655-663(2002).
Green A.R.,et al.Breast Cancer Res. Treat. 113:59-66(2009).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.